

Cover Story
This was not your ordinary ODAC, but a three-day checkpoint inhibitor marathon that consumed April 27, 28, and 29. You might call it six ODACs for the price of one: subtle as all get-out, if-you-blink-you-miss-it head-spinner of a shindig.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Mikaela Naylon Give Kids a Chance Act nixed by Senate
- Should I have a drink tonight?
In anticipation of the first holiday season since the surgeon general’s report on alcohol and cancer, we ask experts to weigh in - Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- The Cancer Letter’s most-read stories of 2025
As MAHA-led policies took hold, oncology navigated through uncertainty and turmoil - Mitochondrial-targeting drug attacks cancer cells from within
- With streamlined, “sitevisitless” CCSG review in place, cancer centers remained stable in 2025

















